Search Results

You are looking at 1 - 1 of 1 items for

  • Author: John Costello Jr x
Clear All Modify Search
Joanna Klubo-Gwiezdzinska National Institute of Health, NIDDK, Office 10 Center Drive, Bethesda, Maryland, USA
Division of Endocrinology, Department of Medicine, Medstar Washington Hospital Center, Washington Hospital Center, Northwest, Washington, District of Columbia, USA

Search for other papers by Joanna Klubo-Gwiezdzinska in
Google Scholar
PubMed
Close
,
John Costello Jr Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA

Search for other papers by John Costello Jr in
Google Scholar
PubMed
Close
,
Kirk Jensen Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA

Search for other papers by Kirk Jensen in
Google Scholar
PubMed
Close
,
Aneeta Patel Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA

Search for other papers by Aneeta Patel in
Google Scholar
PubMed
Close
,
Rok Tkavc Department of Pathology, Uniformed Services University of the Health Sciences, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA

Search for other papers by Rok Tkavc in
Google Scholar
PubMed
Close
,
Douglas Van Nostrand Division of Endocrinology, Department of Medicine, Medstar Washington Hospital Center, Washington Hospital Center, Northwest, Washington, District of Columbia, USA

Search for other papers by Douglas Van Nostrand in
Google Scholar
PubMed
Close
,
Kenneth D Burman Division of Endocrinology, Department of Medicine, Medstar Washington Hospital Center, Washington Hospital Center, Northwest, Washington, District of Columbia, USA

Search for other papers by Kenneth D Burman in
Google Scholar
PubMed
Close
,
Leonard Wartofsky Division of Endocrinology, Department of Medicine, Medstar Washington Hospital Center, Washington Hospital Center, Northwest, Washington, District of Columbia, USA

Search for other papers by Leonard Wartofsky in
Google Scholar
PubMed
Close
, and
Vasyl Vasko Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA

Search for other papers by Vasyl Vasko in
Google Scholar
PubMed
Close

Background

Amifostine is a potent scavenger of reactive oxygen species that is used for the salivary gland protection during therapy with radioactive iodine for thyroid cancer. There are no data on the potential effect of amifostine on thyroid cancer cells.

Methods

We investigated the effects of the active form of amifostine (WR-1065) on the response of thyroid cancer cells to treatment with DNA-damaging agents. WR-1065 was examined in human thyroid cancer cell lines (FTC133, TPC1, BCPAP and C643) and embryonic fibroblast cells NIH3T3. DNA damage was induced by exposure to H2O2 (0.1 mM), by treatment with the radiomimetic neocarzinostatin (NCS 250 ng/mL) and by γ-radiation (6 Gy). DNA damage, cell viability and apoptosis were examined.

Results

We demonstrated the selective action of WR-1065 (0.1 mM), which prevented oxidative stress–induced DNA damage in fibroblasts, but did not protect thyroid cancer cells from DNA damage and apoptosis documented by caspase-3 and PARP cleavage after exposure to H2O2, NCS and γ-radiation. Prolonged exposure to WR-1065 (0.1 mM for 24 h) was toxic for thyroid cancer cells; this treatment decreased the number of viable cells by 8% in C643 cells, 47% in TPC cells, 92% in BCPAP cells and 82% in FTC 133 cells. The cytotoxic effects of WR-1065 were not associated with induction of apoptosis.

Conclusions

Our data show that amifostine has no protective effect on thyroid cancer cells against DNA-damaging agents in vitro and suggest that amifostine will not attenuate the efficacy of radioiodine treatment in patients with thyroid cancer.

Open access